Overview
- Gilead’s Trodelvy won U.S. FDA first‑line approval Wednesday and received European Commission marketing authorisation as a monotherapy for adults with unresectable or metastatic triple‑negative breast cancer who are not candidates for PD‑1/PD‑L1 inhibitors.
- The EC decision and the FDA approval rest on the phase 3 ASCENT‑03 trial, in which Trodelvy cut the risk of disease progression or death by about 38% versus standard chemotherapy in the first‑line population studied.
- AstraZeneca and Daiichi Sankyo’s Datroway was approved in May for a similar first‑line group after a separate trial showed a roughly 43% progression risk reduction and an about five‑month median overall survival gain, but no head‑to‑head data exist between the two drugs.
- Both companies are moving these antibody‑drug conjugates into neoadjuvant and adjuvant studies to test whether the drugs can shrink tumors before surgery or clear leftover cancer cells, and guideline updates plus payer coverage will shape how quickly clinicians adopt them.
- Triple‑negative breast cancer is an aggressive subtype that affects about 15% of breast cancers and disproportionately hits younger, Black and Hispanic women, so faster access to more effective first‑line options could materially change patient outcomes if survival gains and equity in access are secured.